SCHEMBL21136730

SCHEMBL21136730

CC1CN(c2c(N(C)C=O)cnc3c2cc(Cl)c2c3oc3cccc(F)c32)CCN1C(=O)/C=C/CN(C)C

nearest known ligand 0.37

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KRAS P01116 9/20 0.37
CHRM1 P11229 1/20 0.32
EGFR P00533 5/20 0.32
ERBB2 P04626 1/20 0.32
CCNK O75909 3/20 0.32
CDK12 Q9NYV4 3/20 0.32
JAK3 P52333 2/20 0.31
BTK Q06187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21136902 0.91 KRAS (0.41) KRAS
SCHEMBL21136805 0.78 HRH4 (0.40) KRAS
SCHEMBL21137333 0.77 MAPK8 (0.38) KRAS
SCHEMBL21136897 0.72 SUV39H2 (0.42) KRASEGFR
SCHEMBL21137341 0.70 TP53 (0.35)
SCHEMBL21137480 0.69 MAP4K4 (0.40) KRASEGFR
SCHEMBL21137567 0.67 HRH4 (0.38) KRASEGFRBTK
SCHEMBL21050633 0.66 KRAS (0.64) KRASEGFR
SCHEMBL21137066 0.64 KRAS (0.70) KRAS
SCHEMBL21137055 0.62 KRAS (0.34) KRASEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019110751-A1 TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2019-06-13 WO disclosed